BAXTER Company Profile

What is the competitive landscape for BAXTER, and when can generic versions of BAXTER drugs launch?

BAXTER has two hundred and twenty approved drugs.

There are twenty-two US patents protecting BAXTER drugs. There are two tentative approvals on BAXTER drugs.

There are forty patent family members on BAXTER drugs in thirteen countries and three hundred and fifteen supplementary protection certificates in sixteen countries.

Summary for BAXTER

International Patents:	40
US Patents:	22
Tradenames:	333
Ingredients:	131
NDAs:	220
PTAB Cases with BAXTER as patent owner:	See PTAB cases with BAXTER as patent owner

Drugs and US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TRAVASOL 10% W/O ELECTROLYTES	amino acids	INJECTABLE;INJECTION	017493-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER	sodium chloride	INJECTABLE;INJECTION	019022-002	Nov 1, 1983	AP	RX	Yes	No
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	10,543,186
Baxter Hlthcare	TRAVASOL 8.5% W/ ELECTROLYTES	amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride	INJECTABLE;INJECTION	017493-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER	potassium chloride	INJECTABLE;INJECTION	019904-006	Dec 17, 1990	AP	RX	Yes	Yes
Baxter Hlthcare	TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019520-001	Sep 23, 1988		DISCN	No	No
Baxter Hlthcare Corp	DAPTOMYCIN IN 0.9% SODIUM CHLORIDE	daptomycin	SOLUTION;INTRAVENOUS	213645-005	Feb 27, 2023		RX	Yes	Yes

Expired US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-006	Feb 25, 2003	6,310,094*PED
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	8,133,883
Baxter Hlthcare Corp	DOXIL (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	050718-002	Jun 13, 2000	5,213,804
Baxter Hlthcare	LYOPHILIZED CYTOXAN	cyclophosphamide	INJECTABLE;INJECTION	012142-006	Dec 5, 1985	4,537,883
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	4,882,452
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-003	Oct 10, 1992	4,882,452
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	4,220,660

Paragraph IV (Patent) Challenges for BAXTER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31
	Inhalation	99.90%		2008-09-11

International Patents for BAXTER Drugs

Country	Patent Number	Estimated Expiration
Japan	2017019879
Japan	6444548
South Korea	101314803
European Patent Office	4117625
South Korea	20110010742
Hong Kong	1219883
Canada	2702603

Supplementary Protection Certificates for BAXTER Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2563920	CR 2019 00001	Denmark		PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
2465580	SPC/GB21/030	United Kingdom		PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221
1527050	C 2014 034	Romania		PRODUCT NAME: BEDAQUILINA SAU O SARE DE ADITIE A UNUI ACID SAU A UNEI BAZEACCEPTABILA FARMACEUTIC A IN-3-IL)-4-(DIMETILAMINO)-2-(NAFTALEN-1-IL)-1-FENILBUTAN-2-OL; NATIONAL AUTHORISATION NUMBER: EU/1/13/901; DATE OF NATIONAL AUTHORISATION: 20140305; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/901; DATE OF FIRST AUTHORISATION IN EEA: 20140305 ACESTEIA, INCLUSIV FUMARAT DE BEDAQUILINA - FUMARAT DE BEDAQUILINA (1R,2S)-1-(6-BROMO-2-METOXIQUINOL
2340828	PA2021502	Lithuania		PRODUCT NAME: SAKUBITRILAS/VALSARTANAS, KAIP SAKUBITRILO VALSARTANO NATRIO DRUSKOS KOMPLEKSAS, T.Y. (((S)-N-VALERIL-N-((2'-(1H-TETRAZOL-5-IL)-BIFENIL-4-IL)-METIL)-VALINAS)((2R,4S)-5-BIFENIL-4-IL-4-(3-KARBOKSI-PROPIONILAMINO)-2-METIL-PENTANO RUGSTIES ETILO ESTERIS)NA3; REGISTRATION NO/DATE: EU/1/15/1058 20151119
0484186	1190033-9	Sweden		PRODUCT NAME: 4-AMINOPYRIDIN ELLER ETT SALT DAERAV; REG. NO/DATE: EU/1/11/699/001 20110720
1304992	SPC/GB13/061	United Kingdom		PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp